JAZZ Q4 2019 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$11B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$582M+22.1% YoY

Gross Profit

$546M93.9% margin

Operating Income

$61M10.5% margin

Net Income

$74M12.7% margin

EPS (Diluted)

$1.29

QoQ Revenue Growth

+8.2%

Cash Flow

Operating Cash Flow

$88M

Free Cash Flow

$81M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$5.5B

Total Liabilities

$2.4B

Stockholders' Equity

$3.1B

Cash & Equivalents

$637M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$582M	$476M	+22.1%
Gross Profit	$546M	$450M	+21.4%
Operating Income	$61M	$185M	-66.9%
Net Income	$74M	$159M	-53.6%

Revenue Segments

Product And Services, Product Sales

$577M50%

Xyrem

$435M38%

Erwinaze And Erwinase

$55M5%

Defitelio/Defibrotide

$48M4%

Vyxeos

$32M3%

Product And Services, Royalties And Contract Revenue

$5M0%

Other Products

$4M0%

Sunosi

$3M0%

Geographic Segments

UNITED STATES

$529M91%

Europe

$43M7%

Other Countries

$9M2%